Industry Funding Opportunities

For all InPart Funding Listings please Contact Brian Roe

Anonymous - Kidney Disease Focused Drug Discovery and Early Pre-Clinical Development

InPart Funding
Therapeutics and Vaccines

Deadline: November 22nd 2021  Our client is a Japan-based global pharmaceutical company that has a passion for contributing to human health through innovative drug discovery, driven by state-of-the-art technologies in nephrology, one of its core therapeutic areas. Our client is interested in early-stage drug discovery and preclinical research to identify next generation small molecule and biologics (including antibody approaches and protein therapeutics) approaches to treat kidney diseases with high unmet needs.

Open Anonymous - Kidney Disease Focused Drug Discovery and Early Pre-Clinical Development PDF

Ultragenyx - Research Programme for Rare and Ultra-Rare Diseases

InPart Funding
Therapeutics and Vaccines

Deadline: November 22nd 2021 Ultragenyx is a biopharmaceutical company focused on developing novel products for the treatment of rare and ultra-rare diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease

Open Ultragenyx - Research Programme for Rare and Ultra-Rare Diseases PDF

Ultragenyx - Next Generation Gene Regulation Technology Applicable for AAV‑Based Gene Therapy

InPart Funding
Therapeutics and Vaccines

Deadline: November 22nd 2021 Ultragenyx is a biopharmaceutical company focused on developing novel products for the treatment of rare and ultra rare diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease

Open Ultragenyx - Next Generation Gene Regulation Technology Applicable for AAV‑Based Gene Therapy PDF

Anonymous - New Therapeutic Strategies Targeting Myeloid Malignancies

InPart Funding
Therapeutics and Vaccines

Deadline: October 25th 2021 A global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations wishes to identify therapeutic targets and/or therapeutic assets that target Myeloid Malignancies, specifically Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN).  

Open Anonymous - New Therapeutic Strategies Targeting Myeloid Malignancies PDF

Benitec Biopharma - Monogenic Targets for RNA Interference- Based Therapy

InPart Funding
Therapeutics and Vaccines

Deadline: November 1st 2021 Benitec Biopharma is an American biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy for the goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. Benitec Biopharma are seeking research focused on the identification of monogenic targets (both dominant and recessive) that can be downregulated by expressed RNAi and replaced with a RNAi insensitive transgene.

Open Benitec Biopharma - Monogenic Targets for RNA Interference- Based Therapy PDF

BioMarin Pharmaceuticals - Genetically Based Research in Nephrology

InPart Funding
Therapeutics and Vaccines

Deadline: November 15th 2021 BioMarin Pharmaceutical Inc. is a world leader in developing and commercialising first- or best-in-class therapies for rare genetic diseases. BioMarin Pharmaceutical Inc. is looking for early discovery research that involve targets with strong genetic evidence in the area of kidney disease, with a focus on Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Alport Syndrome.

Open BioMarin Pharmaceuticals - Genetically Based Research in Nephrology PDF

Johnson & Johnson - Exosome Uptake for Gastrointestinal Tract

InPart Funding
Therapeutics and Vaccines

Deadline: October 18th 2021 Johnson & Johnson Innovation wishes to identify research focused on the mechanism of exosome uptake across the gastrointestinal (GI) epithelium, including identification of the uptake pathway involved, where in the GI tract this occurs, transport kinetics and efficiency, and substrate specificity. Our client is seeking to identify research focused on the mechanism of exosome uptake in the GI tract with a view of applying this knowledge to the oral delivery of macromolecules

Open Johnson & Johnson - Exosome Uptake for Gastrointestinal Tract PDF

Therapeutic Agents for Kidney Repair

InPart Funding
Therapeutics and Vaccines

Deadline: November 8th 2021 Johnson & Johnson Innovation is interested in developing therapeutics for kidney diseases, including Chronic Kidney Disease (CKD), Diabetic Kidney Disease (DKD), Acute Kidney Injury (AKI), Autosomal Dominant Polycystic Kidney Disease (ADPKD), and other selected rare kidney diseases. Johnson & Johnson Innovation is looking for novel compounds, targets or pathways with the objective to repair kidney damage caused by CKD, AKI, or major types of rare kidney diseases.

Open Therapeutic Agents for Kidney Repair PDF